Form 4: Viridian Therapeutics Director Receives New Stock Option Grant

Jennifer K. Moses, a Director at Viridian Therapeutics, Inc., was granted 21,000 stock options with an exercise price of $14.47, vesting over approximately one year.

Summary

• Jennifer K. Moses, a Director of Viridian Therapeutics, Inc. (VRDN), acquired 21,000 stock options.
• The options have an exercise price of $14.47 per share.
• The transaction date for the option grant was July 1, 2025.
• The options become exercisable upon the earlier of July 1, 2026, or the Issuer's 2026 annual meeting of stockholders.
• The options expire on July 1, 2035.
• Vesting is contingent upon Ms. Moses' continued service on the Board of Directors of the Issuer.
• Following this transaction, Ms. Moses beneficially owns 21,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive, as it represents standard director compensation and aligns interests, with no negative implications disclosed.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.

Risks

• The value of the stock options is dependent on the future market price of Viridian Therapeutics' common stock, meaning the options could become worthless if the stock price falls below the exercise price.

Future Outlook

The stock option is designed to vest upon the earlier of July 1, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to the director's continued service.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a form of equity-based compensation to attract and retain qualified board members and align their interests with long-term company success.

Comparison to Industry Standards

• The grant of stock options to board members is a standard compensation practice across publicly traded companies, including those in the biotechnology sector.
• Specific comparisons to the size or terms of option grants at comparable companies (e.g., BioNTech, Moderna, Regeneron) are not detailed in this filing, as it focuses solely on the individual transaction.

Corporate Governance

Related Party Transactions

• The grant of 21,000 stock options to Jennifer K. Moses, a Director, constitutes a related party transaction as it involves compensation provided by the Issuer to a member of its Board of Directors.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock option will vest upon the earlier of July 1, 2026, or the Issuer's 2026 annual meeting of stockholders, provided the director continues service.

Key Dates

Keywords

Viridian Therapeutics, VRDN, Stock Option, Insider Transaction, Director Compensation, Form 4, Equity Grant, Beneficial Ownership